On Friday, the U.S. Food and Drug Administration approved a new indication for Pfizer Inc.’s (NYSE:PFE) Padcev, used in combination with Merck & Co. Inc.’s (NYSE:MRK) Keytruda, for treating muscle-invasive bladder cancer. The decision allows the regimen to be administered before and after bladder-removal surgery in adults, including those eligible for cisplatin chemotherapy. Despite the regulatory green light, Pfizer shares slipped 0.33% to $24.17, reflecting a muted response from Wall Street.
Market Reaction and Trading Volume
Pfizer’s stock declined 0.62% from its July 2 close, underperforming the S&P 500, which rose 1.2% last week. Trading volume on Friday was 27.5 million shares, roughly 31% below the 65-day average, suggesting limited investor enthusiasm. The approval arrived during market hours, yet the stock showed no significant volatility, indicating that the market had largely priced in the decision.
Clinical Data and Competitive Impact
The FDA based its approval on Phase 3 trial results showing a 47% lower risk of recurrence, progression, or death with the Padcev-Keytruda combination compared to standard gemcitabine plus cisplatin. Two-year event-free survival reached 79.4% versus 66.2%, and pathological complete response was 55.8% compared to 32.5%. However, severe adverse events occurred in 75.7% of patients on the combo versus 67.2% on chemotherapy. Pfizer commercial chief Aamir Malik highlighted that this is the first approved platinum-free combination regimen for this setting.
Separately, Pfizer received a competitive boost when AstraZeneca Plc’s (NASDAQ:AZN) Wainua failed to reduce cardiovascular deaths or repeat heart events in a late-stage trial for transthyretin amyloid cardiomyopathy, a condition treated by Pfizer’s Vyndaqel. Analysts had projected peak sales of $2 billion for Wainua, and its setback weakens one of Pfizer’s challengers in the cardiology space.
Financial Implications and Patent Losses
Padcev contributed $165 million in Q1 sales, reaching $591 million, but accounted for only 4.1% of Pfizer’s total revenue. Yet it generated about 22% of the company’s $736 million revenue growth for the quarter. The expanded label is critical because Pfizer faces an estimated $1.5 billion in revenue loss in 2026 due to patent expirations and generic competition. The company’s Q1 results masked the underlying challenges, and investors are seeking evidence that Padcev can offset these declines.
Additionally, a U.S. appeals court upheld the loss of two patents that Pfizer’s Wyeth unit had sought to enforce against AstraZeneca’s Tagrisso, wiping out a $107.5 million award. While not a material sum for Pfizer, the ruling underscores the risks of relying on patent acquisitions for steady returns.
Outlook and Key Catalysts
Pfizer’s dividend of $0.43 per share yields approximately 7.1%, offering income appeal, but the stock lacks growth catalysts. The true sales impact of the Padcev approval will not appear until Q3 results, as the decision came after Q2 closed. Investors will scrutinize Pfizer’s August 4 earnings call for launch strategy details and any adjusted guidance. Upcoming U.S. inflation data (CPI on July 14, PPI on July 15) and retail sales on July 16 could influence broader market sentiment, but Pfizer’s near-term trajectory hinges on Padcev’s commercial uptake.
For shares to rally, Padcev must sustain its Q1 growth trajectory as its label expands. Without accelerated adoption, the FDA approval remains a bet on future potential rather than a catalyst for immediate recovery.
